Vivos Therapeutics (VVOS) Short term Debt (2019 - 2026)
Vivos Therapeutics (VVOS) posted quarterly Short term Debt of $7.3 million for Q1 2026, down 12.62% quarter-over-quarter from $8.4 million in Q4 2025.
Vivos Therapeutics (VVOS) Short term Debt (2019 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported Short term Debt for 5 consecutive years, with $7.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short term Debt changed N/A year-over-year to $7.3 million; the TTM figure through Mar 2026 stood at $7.3 million (changed N/A YoY), while the FY2025 annual figure was $8.4 million, changed N/A from the prior year.
- Short term Debt eased to $7.3 million in Q1 2026 per VVOS's latest filing, from $8.4 million in the prior quarter.
- Across five years, Short term Debt topped out at $8.4 million in Q4 2025 and bottomed at $157000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn |
| 10 | Vivos Therapeutics | 4.94 Mn | 3.14 Mn | 2.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.30 Mn |
| Dec 31, 2025 | 8.35 Mn |
| Sep 30, 2025 | 339,000.00 |
| Jun 30, 2025 | 157,000.00 |
| Dec 31, 2021 | 1.27 Mn |
| Sep 30, 2021 | 1.27 Mn |
| Jun 30, 2021 | 1.27 Mn |
| Mar 31, 2021 | 1.16 Mn |
| Dec 31, 2020 | 867,000.00 |
| Dec 31, 2019 | 3.71 Mn |